Rochester, MNNCT06693336Now EnrollingIRB Ready

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) Clinical Trial in Rochester, MN

Access cutting-edge carcinoma, non-small-cell lung cancer (nsclc) treatment through this clinical trial at a research site in Rochester. Study-provided care at no cost to qualified participants.

Sponsored by ToLymph Inc.

Quick Self-Assessment

See if you qualify for this Rochester location

Preparing your pre-screening questions…

Expert Care in Rochester

Access carcinoma, non-small-cell lung cancer (nsclc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related carcinoma, non-small-cell lung cancer (nsclc) treatment provided free

Apply for This Rochester Location

Check if you qualify for this carcinoma, non-small-cell lung cancer (nsclc) clinical trial in Rochester, MN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Rochester

    Convenient for MN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Rochester site if eligible
  4. 4Begin participation

About This Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) Study in Rochester

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.

Sponsor: ToLymph Inc.

Who Can Participate

Inclusion Criteria

Histopathological confirmed NSCLC
Stage Ib, IIa, IIb or IIIa (N2) for both dose escalation and dose confirmation (NOTE: Staging will be according to the AJCC 8th edition)
Age ≥18 years and suitable for lung cancer surgery
No prior chemotherapy and/or thoracic radiation therapy
Normal liver, and renal function at study entry
Laboratory requirements:
WBC \> 2500/mm3
Neutrophil \>1500/mm3
Hemoglobin \>10 g/dL
Platelet \>100,000/ mm3
AST and ALT \< 2.5 x ULN
Total bilirubin \< 1.5 x ULN
Creatinine \< 2 mg/dL (equivalent to 176.8 μmol/L)
Normal PT/INR and PTT
eGFR \>60mL/min/1.73m²
QT interval corrected for heart rate using Frederica's formula (QTcF): males \< 450msec and females \< 470msec
Operating surgeon deems patient is candidate for complete surgical resection of lung cancer and lymphadenectomy or lymph node sampling (Wedge resection, segmentectomy or lobectomy are acceptable)
Stated willingness to comply with all study procedures and availability for the duration of the study
Ability to understand and sign informed consent
Women of childbearing potential (WOCBP) must use highly effective methods of contraception for at least 6 months after wafer insertion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \[FSH\] ≥40 mIU/mL \[or ≥ 40 IU/L\] if less than 2 y postmenopausal) or be surgically sterile. Men must use highly effective methods of contraception for at least 3 months after wafer insertion. Examples of highly effective contraception include: parenteral contraceptives, oral contraceptives, patch contraceptives, implantable hormonal contraceptives, intrauterine device or system, surgical sterilization (hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy), tubal ligation/occlusion, vasectomized partner, or sexual abstinence, if this is the subject's current practice. Periodic abstinence, i.e., calendar, symptothermal, or post-ovulation methods are not an acceptable form of contraception for this study.

Exclusion Criteria

If a subject meets any of the following criteria, he/she must be excluded from the study.
Evidence of locally advanced T3 or T4 NSCLC or distant metastatic disease.
Patients requiring pneumonectomy or sleeve resection.
Known sensitivity to any of the study agent components.
Patients with a previous malignancy within the last 5 years except non-melanoma skin cancer.
Patients receiving induction (neo-adjuvant) chemotherapy and/or radiation prior to surgery.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. dysfunction of major organ (e.g., liver, kidney etc.), symptomatic congestive heart failure. unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant or nursing female subjects.
Unwilling or unable to follow protocol requirements.
Any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the patient's ability to comply with the study requirements or visit schedule.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Rochester?

Yes, this clinical trial (NCT06693336) has an active research site in Rochester, MN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) Treatment Options in Rochester, MN

If you're searching for carcinoma, non-small-cell lung cancer (nsclc) treatment options in Rochester, MN, this clinical trial (NCT06693336) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Rochester research site is actively enrolling participants for this clinical trial. You'll receive care from experienced carcinoma, non-small-cell lung cancer (nsclc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all carcinoma, non-small-cell lung cancer (nsclc) clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Rochester, MN

See all lung cancer clinical trials recruiting in Rochester — not just this study.

Browse Lung Cancer Trials in Rochester →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsNon-Small Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Rochester?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Rochester, MN